GT BIOPHARMA, INC. Debt Securities, Available-for-sale, Amortized Cost
GT BIOPHARMA, INC. (GTBP) had Debt Securities, Available-for-sale, Amortized Cost of $7.86 million as of 2024-03-31, per its 10-Q filed 2024-05-15.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2025-02-21
- 2024-03-31: Debt Securities, Available-for-sale, Amortized Cost $7.86M.
- 2023-12-31: Debt Securities, Available-for-sale, Amortized Cost $12.85M.
- 2023-09-30: Debt Securities, Available-for-sale, Amortized Cost $13.32M.
- 2023-06-30: Debt Securities, Available-for-sale, Amortized Cost $15.17M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2024-03-31 | $7.86M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $12.85M 10-K · filed 2025-02-21 | |
| 2023-09-30 | $13.32M 10-Q · filed 2023-11-01 | |
| 2023-06-30 | $15.17M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $17.88M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $10.87M 10-K · filed 2024-03-26 | |
| 2022-09-30 | $18.37M 10-Q · filed 2022-10-31 | |
| 2022-06-30 | $18.40M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $26.78M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | $23.04M 10-K · filed 2023-03-30 | $32.01M 10-K · filed 2022-03-28 |
| 2020-12-31 | $5.30M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |